AEON AEON Biopharma, Inc.

$0.26

AEON Biopharma, Inc. (AEON) is expected to report earnings on November 16, 2026, after the market close. The consensus earnings estimate is a loss of $0.07 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -6.3% since its last earnings release on August 12, 2026.

AEON Biopharma Reported Earnings
Wednesday, August 12, 2026 · 4:15 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 16
Monday · 4:15 PM ET
Earnings Whisper
-
vs ($0.07)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $0.27

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About AEON Biopharma, Inc.

AEON Biopharma Inc. is a clinical-stage biopharmaceutical company. It focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions. AEON Biopharma Inc., formerly known as Priveterra Acquisition Corp., is based in IRVINE, Calif.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.